Eating Disorders in Males: Muscle Dysmorphia, Underdiagnosis, and Barriers to Treatment — A Clinical Deep Dive

Eating disorders in males represent one of the most systematically underdiagnosed domains in psychiatric medicine. For decades, anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED) were conceptualized — in research design, diagnostic criteria, screening instruments, and clinical training — as conditions affecting primarily women and girls. This gendered framework has produced a diagnostic blind spot with measurable consequences: males account for an estimated 25% of all eating disorder cases but represent fewer than 10% of individuals receiving treatment in most clinical settings.

The National Institute of Mental Health (NIMH) estimates that lifetime prevalence of AN, BN, and BED in U.S. males is approximately 0.3%, 0.5%, and 2.0%, respectively. However, these figures almost certainly underestimate true prevalence. When subclinical presentations and male-specific phenotypes — particularly muscle dysmorphia (MD), a condition characterized by pathological preoccupation with muscularity and leanness — are included, epidemiological estimates rise substantially. A 2019 meta-analysis by Limbers and colleagues found that disordered eating behaviors affect 10–30% of adolescent males depending on the screening measure used, with rates highest in athletes, sexual minority males, and military populations.

This article examines the neurobiology, epidemiology, diagnostic challenges, comorbidity patterns, treatment outcomes, and systemic barriers that define eating disorders in males, with particular attention to muscle dysmorphia as a male-predominant presentation that sits at the intersection of eating disorder and body dysmorphic disorder (BDD) nosology.

The epidemiological picture of male eating disorders has sharpened considerably over the past two decades, though significant gaps persist due to male underrepresentation in research samples. Key data points from large-scale studies include:

• Anorexia nervosa: Lifetime prevalence in males is approximately 0.1–0.3% (DSM-5-TR). The female-to-male ratio, once cited as 10:1, has been revised to approximately 3:1 to 4:1 in community samples, suggesting that clinical samples dramatically overrepresent the gender disparity. The landmark study by Hudson et al. (2007), using National Comorbidity Survey Replication (NCS-R) data, found a 3:1 female-to-male ratio for AN.
• Bulimia nervosa: Male lifetime prevalence is approximately 0.5%, with a female-to-male ratio of roughly 3:1 in community samples (Hudson et al., 2007). Males with BN are more likely to present with exercise purging rather than self-induced vomiting, contributing to missed diagnoses.
• Binge eating disorder: BED has the most balanced gender distribution of any eating disorder, with a female-to-male ratio of approximately 1.5:1 to 2:1. Lifetime prevalence in males is 1.0–2.0% (DSM-5-TR; NIMH). BED is the most common eating disorder in males.
• Muscle dysmorphia: Prevalence estimates are limited by the absence of standardized diagnostic criteria, but studies suggest MD affects 1–10% of regular gym users and up to 53% of competitive bodybuilders (Pope et al., 2005). Community prevalence in young adult males is estimated at 1–3%.

High-risk populations include sexual minority males (gay and bisexual men show 3- to 7-fold increased risk compared to heterosexual males, per a systematic review by Calzo et al., 2017), transgender men (particularly during and after gender-affirming hormone therapy), combat sport athletes and wrestlers (prevalence of disordered eating 16–33%), military personnel, and men with type 1 diabetes (so-called "diabulimia" via insulin manipulation). Onset age in males tends to be bimodal: adolescence (14–18 years) and a second peak in the mid-20s to 30s, which is later than the typical female onset and may reflect delayed help-seeking rather than true later onset.

Muscle dysmorphia was first described by Pope et al. (1993) as "reverse anorexia nervosa" and later formalized as a subtype of body dysmorphic disorder in the DSM-5 and DSM-5-TR, classified under obsessive-compulsive and related disorders (300.7 / F45.22). However, there is active debate about whether MD is better conceptualized as an eating disorder, a behavioral addiction, or a distinct diagnostic entity. Its nosological placement has significant implications for treatment selection and insurance coverage.

Core Features

The proposed diagnostic features of MD, based on the criteria operationalized by Pope et al. (1997) and the Muscle Dysmorphic Disorder Inventory (MDDI), include:

• Preoccupation with the idea that one's body is insufficiently muscular or lean, despite being objectively muscular or of normal build
• Compulsive exercise (often exceeding 2–4 hours daily), rigid adherence to dietary protocols, and frequent body checking
• Avoidance of situations involving body exposure (beaches, pools, intimate settings)
• Use of anabolic-androgenic steroids (AAS) or other appearance- and performance-enhancing drugs (APEDs) — estimated in 25–65% of individuals with MD
• Clinically significant distress or impairment in social, occupational, or interpersonal functioning
• The preoccupation is not better explained by another mental disorder

The Drive for Muscularity vs. Drive for Thinness

A critical clinical distinction: the drive for muscularity (DFM) in males is not the inverse of the drive for thinness in females — it is a qualitatively different motivational construct. McCreary and Sasse (2000) developed the Drive for Muscularity Scale (DMS) demonstrating that DFM involves both muscularity-oriented body image and muscularity-related behavioral components (supplement use, overtraining). Males with eating disorders frequently pursue a simultaneous increase in muscle mass and decrease in body fat — a goal that produces dietary and exercise patterns distinct from the restriction-only or binge-purge patterns traditionally assessed by eating disorder screening tools.

This "lean muscularity" ideal drives behaviors including rigid macronutrient tracking (with protein intake sometimes exceeding 3–4 g/kg/day), carbohydrate cycling, extreme caloric restriction followed by refeeding, and the use of thermogenic supplements. These patterns may meet criteria for AN (restrictive subtype) or OSFED (atypical AN) but are routinely missed because the individual appears muscular or maintains normal BMI.

The neurobiology of eating disorders in males is underresearched relative to female samples, but converging evidence from neuroimaging, genetics, and neuroendocrinology points to several specific mechanisms.

Serotonergic Dysfunction

Serotonin (5-HT) system dysregulation — particularly involving the 5-HT2A and 5-HT1A receptor subtypes — is implicated in both restrictive and binge-purge eating pathology across sexes. In males with AN, reduced cerebrospinal fluid 5-HIAA (the primary serotonin metabolite) and altered 5-HT2A receptor binding in the mesial temporal and cingulate cortex have been documented. Walter Kaye's research program has demonstrated that individuals recovered from AN show persistent 5-HT2A receptor upregulation in the cingulate and parietal cortex, suggesting trait-level serotonergic vulnerability rather than a state-dependent effect of starvation. In muscle dysmorphia, serotonergic mechanisms are hypothesized to underlie the obsessive-compulsive features (body checking, mirror rituals, dietary rigidity), providing a theoretical rationale for SSRI treatment.

Dopaminergic and Reward Circuitry

Binge eating disorder — the most common eating disorder in males — involves dysregulation of the mesolimbic dopamine system. Functional MRI studies show that males with BED exhibit heightened ventral striatal activation in response to food cues, paralleling patterns seen in substance use disorders. The D2 receptor availability hypothesis, initially demonstrated in obesity by Wang et al. (2001), suggests that reduced striatal D2 receptor density may create a reward deficit state that drives compulsive eating. In muscle dysmorphia, the rewarding properties of exercise (via endorphin and endocannabinoid release) and the reinforcing effects of AAS (which interact with the dopaminergic reward system) create additional pathways for compulsive behavior maintenance.

Hypothalamic-Pituitary-Gonadal (HPG) Axis

Males with AN develop profound HPG axis suppression, with testosterone levels falling to hypogonadal ranges (often <200 ng/dL, sometimes <100 ng/dL). This hormonal disruption produces fatigue, decreased libido, loss of bone mineral density, depressed mood, and cognitive impairment. Paradoxically, males with MD who use exogenous testosterone or AAS experience supraphysiological testosterone states followed by post-cycle crashes with severe hypogonadism, mood instability, and suicidal ideation. This iatrogenic hormonal volatility represents a unique clinical risk factor in this population. The hypothalamic peptide systems — including ghrelin, leptin, and orexin — show sex-differentiated responses to energy restriction, which may contribute to the distinct clinical presentations of male AN.

Genetic Factors

Twin studies estimate the heritability of eating disorders at 50–80% across sexes. The Anorexia Nervosa Genetics Initiative (ANGI) and the Psychiatric Genomics Consortium's Eating Disorders Working Group identified the first genome-wide significant locus for AN on chromosome 12 (Watson et al., 2019), with significant genetic correlations with OCD (rg = 0.44), major depression (rg = 0.42), and — critically — negative genetic correlations with BMI and metabolic traits, suggesting that AN is both a psychiatric and metabolic disorder. Male-specific genetic analyses are severely underpowered due to small sample sizes, but preliminary data suggest shared genetic architecture with females. The COMT Val158Met polymorphism, which influences prefrontal dopamine catabolism, has been tentatively associated with BDD and muscle dysmorphia, though findings require replication.

Neural Circuit Abnormalities

Neuroimaging studies in eating disorders identify dysfunction in three core circuits: (1) the fronto-striatal circuit (impaired cognitive flexibility and set-shifting), (2) the insula-amygdala circuit (altered interoception and threat processing), and (3) the ventromedial prefrontal-ventral striatal circuit (aberrant reward valuation). Males with AN show impaired set-shifting performance on tasks like the Wisconsin Card Sorting Test, comparable to female AN patients. In muscle dysmorphia, preliminary fMRI data suggest exaggerated amygdala responses to images of muscular male bodies and attenuated activation in the fusiform face area during self-body processing, indicating distorted body-related perceptual processing.

The underdiagnosis of eating disorders in males is not simply a matter of lower prevalence — it reflects systematic biases at every level of the diagnostic pipeline. Research consistently shows a median diagnostic delay of 4–5 years in males compared to 2–3 years in females.

Screening Instrument Bias

The most widely used eating disorder screening tools — the Eating Attitudes Test (EAT-26), the Eating Disorder Examination Questionnaire (EDE-Q), and the SCOFF — were developed and validated predominantly in female samples. These instruments emphasize the drive for thinness and weight loss behaviors but do not assess the drive for muscularity, excessive exercise for muscle gain, protein-obsessive dieting, or AAS use. The EDE-Q in particular uses language and thresholds calibrated for female body composition norms. Males who score below clinical cutoffs on these measures may nonetheless have severe eating pathology. The Eating Disorder Assessment for Men (EDAM) and the Male Body Attitudes Scale (MBAS) represent improvements but are not yet widely adopted in clinical practice.

BMI-Centric Diagnostic Criteria

DSM-5-TR criteria for AN require "significantly low body weight" (Criterion A), operationalized as BMI <18.5 kg/m² in adults. Males with eating disorders are more likely to present with normal or elevated BMI due to preserved muscle mass, higher baseline lean mass, or the lean-muscularity phenotype. This means that males with severe caloric restriction, medical instability, and profound psychological distress may not meet Criterion A and receive a diagnosis of OSFED (atypical AN) instead — a designation associated with lower clinical urgency, reduced insurance authorization, and less intensive treatment referral. Studies suggest that males with atypical AN show equivalent or greater medical complications compared to males meeting full AN criteria.

Clinician Gender Bias

A landmark experimental study by Currin et al. (2007) and subsequent studies by Räisänen and Hunt (2014) demonstrated that clinicians presented with identical case vignettes were significantly less likely to diagnose an eating disorder when the patient was identified as male. Primary care physicians in particular report lower confidence in assessing eating disorders in male patients, and many treatment programs historically excluded males or lacked male-specific programming.

Patient Disclosure Barriers

Males with eating disorders report high levels of shame, stigma, and perceived emasculation associated with having a "female" illness. Qualitative research consistently identifies themes of double stigma — the stigma of mental illness compounded by the stigma of having a condition perceived as incongruent with masculine identity. This leads to concealment, minimization, and delayed help-seeking. Gay and bisexual males face additional barriers related to minority stress, and may not disclose disordered eating behaviors in LGBTQ+ health settings that are not specifically designed to assess these conditions.

Differential Diagnosis Pitfalls

Male eating disorder presentations are frequently misdiagnosed as:

• Major depressive disorder (weight loss and appetite change attributed to depression alone)
• Obsessive-compulsive disorder (dietary and exercise rituals classified as OCD without recognition of body image pathology)
• Orthorexia (currently not a formal DSM diagnosis, but often used as a euphemistic label that diverts from eating disorder treatment)
• Overtraining syndrome (exercise compulsion framed as an athletic issue rather than a psychiatric symptom)
• Substance use disorder (AAS and APED use treated in addiction frameworks without addressing underlying body dysmorphia)

Psychiatric comorbidity in males with eating disorders is the rule rather than the exception, with rates comparable to or exceeding those in female patients. Comorbidity profiles, however, show sex-differentiated patterns that influence treatment planning.

Mood Disorders

Major depressive disorder is comorbid in 40–60% of males with AN and 50–70% of males with BN, consistent with rates in females. However, males with eating disorders show a higher prevalence of bipolar spectrum disorders — estimated at 8–15% vs. 3–5% in the general population — which has treatment implications, as mood stabilizers are preferred over SSRIs in bipolar comorbidity.

Anxiety and Obsessive-Compulsive Disorders

Anxiety disorders are present in 55–70% of males with eating disorders. OCD co-occurs in approximately 20–35% of males with AN, compared to 10–15% in the general eating disorder population. In muscle dysmorphia, OCD comorbidity may exceed 30%, consistent with the DSM-5-TR classification of MD under the OCD spectrum. Social anxiety disorder is particularly prevalent, present in 30–50% of males with eating disorders, and often drives avoidance of body exposure situations.

Substance Use Disorders

Males with eating disorders have notably higher rates of comorbid substance use compared to females with eating disorders. Alcohol use disorder co-occurs in 20–35% of males with BN (Strother et al., 2012). The use of anabolic-androgenic steroids (AAS) represents a unique comorbidity: an estimated 3–4 million Americans have used AAS, with prevalence highest in males aged 20–35. In muscle dysmorphia specifically, AAS use rates range from 25% to 65%, creating compounded medical risks including hepatotoxicity, cardiomyopathy, dyslipidemia, and neuropsychiatric effects (aggression, psychosis, depression during withdrawal).

Autism Spectrum Disorder

Emerging research identifies a significant overlap between autism spectrum disorder (ASD) and eating disorders in males. Estimates suggest 20–35% of males in inpatient eating disorder settings meet criteria for ASD or show elevated autistic traits. Cognitive rigidity, sensory sensitivities affecting food texture and temperature tolerance, interoceptive deficits, and alexithymia may represent shared neurocognitive mechanisms. ASD comorbidity predicts poorer treatment response with standard CBT-based protocols and may require adapted treatment approaches.

Suicidality

Males with eating disorders demonstrate elevated suicide risk. AN has the highest mortality rate of any psychiatric disorder (standardized mortality ratio [SMR] of 5.86 in the Arcelus et al. 2011 meta-analysis), and approximately 20% of these deaths are due to suicide. Males with AN may have an even higher SMR than females, though confidence intervals overlap due to small male sample sizes. Suicide attempt rates in males with BN are approximately 15–25%, and the presence of comorbid AAS use, substance abuse, or bipolar disorder significantly increases this risk.

The evidence base for treating eating disorders in males is limited by the historical exclusion or underrepresentation of males in clinical trials. Most treatment recommendations are extrapolated from predominantly female samples, and male-specific randomized controlled trials remain exceedingly rare.

Cognitive-Behavioral Therapy (CBT)

CBT-Enhanced (CBT-E), developed by Christopher Fairburn, is the most evidence-supported psychotherapy for bulimia nervosa and binge eating disorder. In the landmark transdiagnostic trial by Fairburn et al. (2009), CBT-E produced remission rates of 50–60% in BN and 55–65% in BED across 20 sessions. However, male participants constituted fewer than 10% of the sample. Subsequent studies including mixed-gender samples have generally found comparable response rates in males, though male-specific moderator analyses are rarely powered to detect differences. For BED specifically, CBT demonstrates a number needed to treat (NNT) of approximately 3–4 for binge abstinence relative to waitlist controls.

For muscle dysmorphia, CBT protocols adapted from BDD treatment (e.g., Wilhelm et al., 2013) incorporate exposure and response prevention (ERP) targeting mirror checking, body avoidance, and compulsive exercise. Open trial data suggest response rates of 50–70% for BDD-focused CBT, but no RCTs have been conducted specifically in MD populations.

Family-Based Treatment (FBT)

FBT (the Maudsley method) is the first-line treatment for adolescent AN. In the landmark trials by Lock et al. (2010), FBT produced full remission rates of approximately 40–50% at end of treatment, with male adolescents included but rarely analyzed separately. Clinical experience suggests that FBT is effective in male adolescents, though family dynamics may differ — fathers may be less engaged in treatment, and the cultural normalization of dieting and exercise in males may make parents slower to recognize restrictive pathology.

Pharmacotherapy

Pharmacological treatment in male eating disorders follows the general evidence base with important sex-specific considerations:

• Fluoxetine (60 mg/day) is the only FDA-approved medication for BN, with an NNT of approximately 9 for binge-purge abstinence relative to placebo (Bacaltchuk & Hay, 2003 Cochrane review). Male-specific response data are sparse but appear comparable.
• Lisdexamfetamine (50–70 mg/day) is FDA-approved for moderate-to-severe BED, with NNT of approximately 4–5 for binge day cessation in the pivotal trials. Again, male-specific subgroup analyses are limited.
• SSRIs (fluoxetine, fluvoxamine) are used off-label for muscle dysmorphia based on the BDD evidence base. Phillips et al. demonstrated response rates of 53–73% for SSRIs in BDD, with the caveat that high doses are often required (e.g., fluoxetine 60–80 mg). MD-specific SSRI trial data are lacking.
• Olanzapine (2.5–10 mg) has shown modest efficacy for weight restoration in AN in the trial by Attia et al. (2019), with a small but significant effect on BMI gain. Its use in males requires monitoring for metabolic side effects, particularly in those with concurrent AAS-related dyslipidemia.
• No pharmacotherapy has demonstrated efficacy for the core psychopathology of AN (weight phobia, body image distortion). This finding was reinforced by the negative results of the Bulik et al. (2023) DFREEZE trial of dronabinol for AN.

Residential and Inpatient Treatment

Males in residential eating disorder treatment show comparable response rates to females on measures of weight restoration and eating pathology reduction, but several studies report that males experience greater feelings of isolation and gender incongruence in predominantly female treatment environments. Mixed-gender programs that include male peer groups and male-specific psychoeducation show better retention. Dropout rates in eating disorder treatment overall are approximately 20–40%, with some evidence that males have higher early dropout in programs that do not address male-specific concerns.

Understanding prognostic factors is essential for treatment planning and accurate prognosis communication. While the literature on male-specific predictors is developing, several factors have been identified:

Positive Prognostic Indicators

• Shorter duration of illness before treatment initiation: Consistently the strongest predictor of full recovery across eating disorder diagnoses and sexes. Males who receive treatment within 3 years of onset show substantially higher remission rates.
• Absence of comorbid substance use disorder: Active AAS or alcohol use disorder significantly complicates treatment and predicts poorer outcomes.
• Higher pre-treatment motivation to change: Measured by the Stages of Change model, males in the action stage at intake show 2–3 fold higher treatment completion rates.
• Social support and relationship quality: Males in stable relationships or with engaged family support show better outcomes in both FBT and adult treatments.
• BED diagnosis (vs. AN or BN): BED generally has the most favorable prognosis, with long-term remission rates of 60–70% following evidence-based treatment.

Negative Prognostic Indicators

• Comorbid personality disorder: Particularly Cluster B traits (borderline and narcissistic), which are associated with treatment dropout and poor therapeutic alliance. Prevalence of personality disorder comorbidity in males with eating disorders is estimated at 20–35%.
• Severe muscle dysmorphia with AAS dependence: This combination creates physiological dependence, HPG axis suppression, and body image distortion that is highly treatment-resistant.
• Comorbid ASD: As noted, autistic traits predict reduced responsiveness to standard CBT and FBT, necessitating adapted approaches.
• Low BMI at presentation (in AN): BMI <15 at treatment entry predicts longer time to weight restoration and higher relapse rates.
• History of childhood trauma: Present in 30–50% of males with eating disorders and associated with more severe psychopathology, higher comorbidity burden, and poorer treatment response.

Long-Term Outcomes

Long-term outcome data for males remain limited. In AN, the 20-year follow-up literature (primarily from the Zipfel et al. 2000 study and related cohorts) suggests that approximately 50% of AN patients achieve full recovery, 30% achieve partial recovery, and 20% remain chronically ill. Male-specific data suggest similar or slightly better recovery trajectories, though with wider confidence intervals. Crude mortality rates for AN are approximately 5% per decade of illness, with the highest risk in the first 5 years after diagnosis. For BED, long-term outcomes are more favorable: 5-year remission rates approach 65–70%, though weight management remains a persistent challenge.

The treatment gap for males with eating disorders — the difference between those who need treatment and those who receive it — is estimated at 70–80%, substantially wider than the approximately 50–60% treatment gap for females. This disparity reflects multiple interacting barriers:

Structural Barriers

• Treatment program availability: Historically, many residential and intensive outpatient programs were female-only or lacked male beds. While this has improved, geographic access remains limited, particularly in rural areas.
• Insurance and diagnostic barriers: Insurance authorization often requires a formal DSM-5-TR eating disorder diagnosis with BMI criteria. Males who present with muscle dysmorphia (classified under BDD) or atypical AN (normal BMI) may not meet authorization thresholds for intensive treatment.
• Screening and detection: Primary care and emergency settings — the most common first points of clinical contact — have low detection rates for male eating disorders. A UK study found that GPs correctly identified eating disorders in males only 8% of the time in standardized patient encounters.

Cultural and Gender-Norm Barriers

Dominant masculinity norms discourage emotional vulnerability, mental health help-seeking, and identification with conditions perceived as feminine. The framing of eating disorders in public health campaigns, educational materials, and even DSM-5-TR text descriptions uses predominantly female examples and language. Males with eating disorders report feeling invisible, illegitimate, and unwelcome in treatment spaces. The "real men don't get eating disorders" narrative functions as a powerful barrier to self-identification, disclosure, and help-seeking.

For sexual minority males, additional complexity arises from body image pressures within gay male communities (where muscularity and leanness are often heavily valued) combined with minority stress. Conversely, LGBTQ+-affirming health settings may not routinely screen for eating pathology, creating another detection gap.

Provider-Level Barriers

A survey of eating disorder treatment providers (Dearden & Mulgrew, 2013) found that many clinicians felt inadequately trained to treat males, were uncertain about adapting evidence-based treatments for male presentations, and lacked confidence in assessing muscle dysmorphia or AAS use. Male patients in mixed-gender group therapy report feeling silenced, tokenized, or unable to discuss male-specific concerns including muscularity-oriented body image, sexual performance anxiety, and steroid use.

Certain male subpopulations face particularly elevated risk and warrant targeted clinical attention.

Male Athletes

Relative Energy Deficiency in Sport (RED-S), the updated framework replacing the Female Athlete Triad, explicitly recognizes males. Male athletes in weight-class sports (wrestling, boxing, MMA), aesthetic sports (gymnastics, figure skating, diving), and endurance sports (distance running, cycling) show disordered eating prevalence of 16–45% depending on sport and measurement method. A landmark study by Sundgot-Borgen and Torstveit (2004) in Norwegian elite athletes found that 8% of male athletes met clinical eating disorder criteria compared to 0.5% of male controls. RED-S consequences in males include testosterone suppression, decreased bone mineral density (with stress fracture risk), impaired immune function, and cardiovascular compromise.

Military Personnel

Male military personnel face unique body composition requirements that may promote disordered eating. Studies of U.S. military populations have found that 5–12% of active-duty males engage in clinically significant disordered eating behaviors, including extreme weight-cutting practices before physical fitness tests. The culture of physical toughness, pain tolerance, and self-reliance creates additional barriers to disclosure and help-seeking within military health systems.

Transgender Males

Transgender males (assigned female at birth) represent a particularly high-risk group, with eating disorder prevalence estimated at 4–16 times that of cisgender males. Body dissatisfaction may center on sex-specific characteristics (chest, hips) and interact with gender dysphoria in complex ways. Gender-affirming testosterone therapy may improve some aspects of body image while creating new body composition concerns. Eating disorder treatment for transgender males requires integration with gender-affirming care and awareness that standard BMI-based criteria may be inappropriate for individuals undergoing hormonal transition.

The field of male eating disorders is at an inflection point, with several key research frontiers that may substantially advance understanding and treatment over the coming decade.

Neuroimaging and Biomarkers

Ongoing research using task-based and resting-state fMRI aims to identify sex-specific neural signatures of body image distortion. Preliminary work by Moody et al. (2017) suggests that males with AN show distinct patterns of insula activation during interoceptive tasks compared to females. The identification of reliable neuroimaging biomarkers could facilitate earlier detection and treatment matching.

Digital Phenotyping and Machine Learning

Social media analysis and digital phenotyping approaches are being developed to detect early signs of muscle dysmorphia and disordered eating in males through linguistic patterns, image posting behaviors, and physical activity tracking data. These approaches raise ethical questions but may address the detection gap.

Genetic Research

The Psychiatric Genomics Consortium Eating Disorders Working Group is actively seeking male participants for genome-wide association studies. Increasing male representation in genetic samples is essential for determining whether the genetic architecture of eating disorders is sex-shared or sex-specific, which has implications for precision medicine approaches.

Male-Specific Treatment Development

Several research groups are developing and piloting male-adapted CBT protocols that incorporate muscularity-oriented body image interventions, AAS psychoeducation, and masculinity-informed therapeutic frameworks. The Body Project for Men, adapted from the Stice dissonance-based prevention program, has shown promising results in university samples for reducing muscle-oriented body dissatisfaction, though large-scale RCT data are not yet available.

Muscle Dysmorphia Formalization

There is growing advocacy for muscle dysmorphia to receive its own diagnostic criteria in future DSM revisions, potentially as an eating or feeding disorder rather than a BDD subtype. This reclassification would improve detection, facilitate research, and expand treatment access. Until then, the nosological ambiguity of MD remains a significant barrier to clinical and research progress.

Limitations of the Current Evidence Base

It must be emphasized that nearly all treatment evidence for male eating disorders is extrapolated from predominantly female samples. No phase III RCT for any eating disorder treatment has been powered to detect sex-specific effects. The field urgently needs male-inclusive and male-specific clinical trials, male-validated screening instruments adopted into routine clinical practice, and longitudinal outcome studies that follow male cohorts over 10+ years.

Based on the current evidence, the following clinical recommendations can be offered for providers working with male patients:

• Screen routinely: All adolescent and young adult males presenting with significant weight change, excessive exercise, or body image concerns should be screened for eating disorders using male-validated instruments where possible (MBAS, EDAM, or DMS in addition to EDE-Q).
• Ask about muscularity concerns: Explicitly inquire about the drive for muscularity, supplement use, AAS use, and exercise compulsion. These topics rarely emerge spontaneously in clinical encounters.
• Do not rely on BMI alone: Assess medical instability (orthostatic vital signs, electrolytes, testosterone, bone density) regardless of BMI. Males with normal BMI can be severely medically compromised.
• Assess comorbidity comprehensively: Screen for depression, anxiety, OCD, substance use (including AAS), ASD traits, and suicidality at intake and longitudinally.
• Adapt treatment language and content: Use gender-neutral or male-specific language in psychoeducation. Address muscularity-oriented body image, not just thinness. Normalize male eating disorders in psychoeducation.
• Ensure male-inclusive treatment environments: Provide access to male peers in group therapy when possible. Train staff on male-specific presentations and concerns.
• Monitor testosterone and bone health: Males with AN should receive testosterone monitoring and DEXA scans. Testosterone replacement may be considered in consultation with endocrinology for persistent hypogonadism after weight restoration.
• Address AAS use directly: If AAS use is present, integrate harm reduction and withdrawal management into the treatment plan. AAS cessation can precipitate severe depression and suicidality, requiring close monitoring.

Eating disorders in males represent a diagnostic and therapeutic challenge that demands both the rigor of evidence-based medicine and the flexibility to adapt frameworks originally designed for female patients. As the field moves toward more inclusive research and clinical practice, the gap between male prevalence and male treatment access must narrow. The lives at stake — marked by the highest mortality rate of any psychiatric condition — demand nothing less.